⚠ Evidence warning: Clinical trials or other evidence do not support the claims that inflammatory bowel disease is the most common driver of recurrent erythema nodosum, that ulcerative colitis is linked to it more often than Crohn's disease, and that low-dose potassium iodide, colchicine or hydroxychloroquine prevent its return. This page keeps it as a report of what people, websites or other media say.
Erythema Nodosum
Erythema nodosum is the most common form of panniculitis — inflammation of the subcutaneous fat. Rather than a disease in itself, it is a reactive inflammatory response triggered by an underlying condition, most often a streptococcal throat infection. The tender, red nodules on the shins usually heal without scarring, and identifying the underlying trigger is the key to preventing recurrence.
- Erythema Nodosum Explained
- How Erythema Nodosum Is Triggered
- Löfgren's Syndrome and Sarcoidosis
- Appearance and Location of the Nodules
- Diagnosis — Clinical vs. Biopsy
- Investigating the Underlying Cause
- Treatment — Addressing the Cause and the Symptoms
- Recurrent Erythema Nodosum
- Key Research Papers
- Connections
- Featured Videos
Erythema Nodosum Explained
Erythema nodosum (EN) is the most common form of panniculitis — inflammatory disease of the fatty layer just beneath the skin. Crucially, it is a septal panniculitis: the inflammation targets the fibrous connective tissue septa that run between fat lobules, not the fat lobules themselves. This distinction matters because it separates EN from the more destructive lobular panniculitides and explains why it heals cleanly.
EN occurs without vasculitis — the blood vessel walls are not attacked. Instead, it is a reactive phenomenon driven by immune-complex deposition and T-cell-mediated delayed hypersensitivity. The body is reacting to something — an infection, a medication, an inflammatory disease — not directly invading the skin.
The result is characteristic: tender, warm, red nodules that appear almost exclusively on the front of both shins, evolve through a bruise-like color progression over a few weeks, and then resolve completely. EN does not ulcerate and usually leaves no scar. The typical course is 3 to 6 weeks, though flares may recur if the underlying trigger persists.
Who gets it: mostly women. Hospital series from Strasbourg (129 people) and Istanbul (100 people) counted 5 and 6 women for each man, and in a Greek series of 132 people, 83% were women. The average age was 31, 37 and 41 years in those three series.
How Erythema Nodosum Is Triggered
An underlying cause is identified in roughly 50% of cases; the remaining 45–50% are classified as idiopathic. In adults, infections account for the majority of identified triggers. The full spectrum includes:
Infections (most common overall cause)
- Streptococcal pharyngitis (Group A Streptococcus) — the leading single cause, particularly in children and young adults. EN typically appears 2–3 weeks after the sore throat, mirroring the timing of post-streptococcal immune responses. A 2007 review lists testing for streptococcal infection, including the anti-streptolysin O (ASO) titer, in the standard evaluation.
- Tuberculosis — primary tuberculosis (TB) infection can trigger EN, especially in endemic regions. A chest X-ray and tuberculin skin test (or interferon-gamma release assay, IGRA) are routine parts of the workup.
- Histoplasmosis and coccidioidomycosis — endemic fungal infections. Coccidioidomycosis-associated EN is sometimes called "desert rheumatism" because the arthralgias accompanying it can mimic rheumatic disease. Relevant in the southwestern United States and Central America.
- Yersinia enterocolitica — particularly common as a cause in northern European countries. Gastrointestinal (GI) symptoms may be mild or absent.
- Chlamydia trachomatis (lymphogranuloma venereum serotypes)
- Bartonella and human immunodeficiency virus (HIV) — less common but reported associations.
Inflammatory and Systemic Diseases
- Sarcoidosis — when EN occurs with bilateral hilar lymphadenopathy and periarthritis, this triad defines Löfgren's syndrome (see next section).
- Inflammatory bowel disease — both ulcerative colitis and Crohn's disease. Ulcerative colitis has been described as associated somewhat more frequently than Crohn's, but in a 2026 clinic series of 95 people with EN and bowel disease, most (80%) had Crohn's disease; that series gives no rate for each disease. EN activity often mirrors bowel disease activity: in the same series, 81% had objective evidence of active bowel disease and 74% had gut symptoms when the EN appeared.
- Behçet's disease — EN-like lesions are a recognized feature and may sometimes be histologically distinct (with vasculitis).
- Cancer — a 2007 review lists cancer among the systemic diseases of which EN may be the first sign, along with tuberculosis, deep fungal infection, sarcoidosis and bowel disease.
Medications
- Oral contraceptives — one of the most common drug causes; estrogen-containing pills are the principal culprit.
- Sulfonamides
- Bromides (less commonly encountered today)
Pregnancy
Pregnancy itself can trigger EN, typically in the first trimester. A pregnancy test is standard in women of childbearing age presenting with EN of unclear cause.
Idiopathic (45–50%)
Despite a thorough workup, nearly half of all cases have no identifiable cause. These tend to be self-limited with a favorable prognosis, though the lack of a treatable trigger makes counseling on recurrence risk more difficult.
The Leading Cause Changes With Place
In Strasbourg, France, 28% of 129 cases followed a confirmed streptococcal infection and only one (0.8%) was tuberculosis. In Istanbul, among 100 cases, streptococcal infection accounted for 11% and primary tuberculosis for 10%. In a Greek series of 132 people, sarcoidosis was the top identified cause at 28%, and no cause was found in 35%.
Löfgren's Syndrome: Erythema Nodosum and Sarcoidosis
Löfgren's syndrome is an acute, self-limited presentation of sarcoidosis defined by a clinical triad: bilateral hilar lymphadenopathy on chest X-ray, erythema nodosum, and periarthritis — typically a warm, swollen ankle arthritis — often accompanied by fever. It represents the most benign form of sarcoidosis and carries an excellent long-term prognosis.
The bilateral hilar adenopathy on chest X-ray is the pivotal finding that distinguishes Löfgren's syndrome from other causes of EN. On the X-ray you see symmetric enlargement of the lymph nodes at both lung roots without parenchymal infiltrates. This appearance, combined with EN and ankle arthritis, is virtually diagnostic and a biopsy of the lymph nodes or skin is usually unnecessary.
Genetic susceptibility plays a clear role: HLA-DRB1*03 is strongly associated with Löfgren's syndrome and is linked to its tendency toward spontaneous resolution. Most patients with Löfgren's syndrome resolve completely without immunosuppressive treatment, though nonsteroidal anti-inflammatory drugs (NSAIDs) or short-course corticosteroids may be needed for symptom control.
An important pitfall: both sarcoidosis and tuberculosis cause bilateral hilar adenopathy and can trigger EN. If there is any clinical concern for tuberculosis — travel history, exposure, immunocompromise — an interferon-gamma release assay or tuberculin test and sputum cultures are the tests used before corticosteroids are started. Steroids can be dangerous in undiagnosed active tuberculosis.
If the diagnosis remains uncertain after chest X-ray, serum angiotensin-converting enzyme (ACE) level and bronchoalveolar lavage (BAL) may help confirm sarcoidosis.
Appearance and Location of the Nodules
The physical appearance of EN is distinctive enough that an experienced clinician can often diagnose it at a glance.
Location: The nodules appear almost exclusively on the anterior shins (pretibial region), bilaterally. They can also occur on the ankles, knees, and forearms, but unilateral or non-shin involvement raises doubt about the diagnosis.
Character: The nodules are oval, 1–5 cm in diameter, deep-seated, firm, and exquisitely tender to the touch. The overlying skin is initially bright red and warm. They do not have a surface change — no pustules, no vesicles, no scale.
Color evolution (the hallmark): Over 3–6 weeks, the nodules evolve through a characteristic color sequence: bright red → brick red → yellow-green → brown-violaceous. This rainbow-like bruise color change — called erythema contusiforme — mimics the appearance of a deep bruise resolving, yet without any trauma having occurred. This "bruise without a bruise" quality is characteristic.
What EN does NOT do:
- It does not ulcerate. Ulceration points to a different diagnosis (such as pyoderma gangrenosum, vasculitis, or erythema induratum).
- It does not usually scar. A 2007 review says it "usually resolves without atrophy or scarring"; healing is described as complete, without pigment change.
- It does not fluctuate or drain.
Systemic features: Most patients have accompanying systemic symptoms: fever (typically low-grade), malaise, fatigue, and arthralgias. The ankle joints are most often affected, and in Löfgren's syndrome the ankle periarthritis may be more prominent than the EN itself.
Diagnosis — Clinical vs. Biopsy
EN is usually a clinical diagnosis. When you see bilateral, tender, warm, red-to-bruise-colored nodules on the anterior shins of a young woman with recent pharyngitis or known inflammatory bowel disease (IBD), the diagnosis is straightforward and a biopsy is not needed.
When to biopsy: If the presentation is atypical — unilateral nodules, lesions that ulcerate, posterior calf location, or failure to resolve in 6–8 weeks — a skin biopsy is appropriate.
Biopsy findings in EN:
- Septal panniculitis without vasculitis — the diagnostic hallmark. Inflammation is confined to the fibrous septa between fat lobules. Fat lobules themselves are initially spared.
- Miescher's radial granulomas — macrophages arranged in a radial (star-shaped) pattern around a central slit-like space; these are the most specific histological finding for EN.
- In older lesions: granulomatous inflammation with giant cells, fibrosis of septa.
Differential diagnosis:
- Cellulitis — typically unilateral, spreading, associated with skin break or lymphedema, fever often higher; lacks the bruise-like color evolution.
- Erythema induratum (Bazin's disease) — lobular panniculitis with vasculitis, associated with tuberculosis; occurs on the posterior calves (not anterior shins); may ulcerate.
- Superficial thrombophlebitis — follows the course of a vein; linear rather than oval nodules.
- Polyarteritis nodosa — involves medium-vessel vasculitis; nodules may ulcerate; associated systemic features differ.
- Pyoderma gangrenosum — ulceration is the defining feature; pathergy positive; associated with inflammatory bowel disease but a completely different entity.
- Deep fungal infections — in immunocompromised patients or endemic areas; may require culture and biopsy to distinguish.
Investigating the Underlying Cause
Finding the underlying trigger is essential — not to treat the EN itself (which resolves on its own) but to treat the driving condition and prevent recurrence. A systematic workup covers the major categories:
- Throat culture and ASO titer — for Group A Streptococcus; the ASO titer may remain elevated for weeks after the acute infection has resolved, making it useful even when the throat culture is negative.
- Chest X-ray — to look for bilateral hilar lymphadenopathy (Löfgren's/sarcoidosis) or primary tuberculosis infiltrates.
- Tuberculin skin test (purified protein derivative) or interferon-gamma release assay — to evaluate for tuberculosis, especially before any immunosuppressive therapy.
- Stool culture and Yersinia serology — particularly relevant in patients with gastrointestinal symptoms or European travel history.
- Antinuclear antibody (ANA) — to screen for connective tissue disease.
- Serum ACE level — elevated in active sarcoidosis; non-specific but supportive.
- Complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) — to characterize the degree of systemic inflammation and monitor treatment response.
- Fungal serology (coccidioides, histoplasma) — in patients from or traveling through endemic areas (southwestern US, Ohio/Mississippi river valleys).
- Pregnancy test — listed for women of childbearing age before treatment starts.
- Medication review — specifically oral contraceptives and sulfonamides; a temporal relationship between starting a new medication and EN onset is a strong clue.
- Inflammatory bowel disease evaluation — if the patient has gastrointestinal symptoms (diarrhea, cramping, rectal bleeding), colonoscopy may be indicated; inflammatory bowel disease can present with EN as the first manifestation before bowel symptoms are obvious.
Most workups can be completed with these initial tests. Additional testing (bronchoalveolar lavage, skin biopsy for culture, computed tomography (CT) chest) is guided by initial results.
Which findings pointed to a hidden cause: in the Istanbul series of 100 people, fever, a raised white cell count, raised C-reactive protein, a fast sedimentation rate, cough, sore throat, diarrhea, arthritis and lung findings all predicted an underlying disease. The Strasbourg authors concluded that "in the absence of specific symptoms, exhaustive investigations are not cost-effective."
Treatment — Addressing the Cause and the Symptoms
The most important treatment principle is straightforward: identify and treat the underlying cause. Streptococcal pharyngitis gets antibiotics (penicillin or amoxicillin). Active tuberculosis gets anti-tuberculosis therapy. Oral contraceptive-induced EN resolves when the pill is stopped. Inflammatory bowel disease-associated EN often improves when the bowel disease is controlled.
EN itself is self-limited and resolves spontaneously in 3–6 weeks without any intervention directed at the skin. Symptomatic management focuses on reducing pain and swelling:
- Rest and leg elevation — simple and effective; gravity pooling of fluid in the lower legs worsens edema and pain.
- Compression bandaging — reduces edema and provides pain relief; particularly helpful when the patient needs to remain ambulatory.
- Nonsteroidal anti-inflammatory drugs (first-line for pain) — indomethacin (25–50 mg three times daily) and naproxen are the most commonly used. They reduce inflammation, fever, and pain, and can shorten the duration of discomfort. In two Istanbul series, all patients had bed rest, most were also given naproxen, and outcomes were "usually favorable within 7 days"; those series had no comparison group.
- Potassium iodide (saturated solution of potassium iodide, SSKI) — second-line, reported effective for persistent or recurrent EN — the mechanism is not fully understood but it has demonstrable anti-inflammatory effects on this specific condition. In a 1976 case series with no comparison group, 24 of 28 people with EN responded, symptoms eased within 2 days, treatment lasted about 3 weeks on average, and the lesions took about 2 weeks on average to resolve. Typical dose is 300–900 mg/day in divided doses. Thyroid disease (hyper- or hypothyroidism) is a listed reason against it, and it is contraindicated in pregnancy.
- Systemic corticosteroids — reserved for severe, debilitating cases. They are highly effective but are used only after infection — especially tuberculosis — has been excluded. Corticosteroids in undiagnosed active tuberculosis can trigger catastrophic dissemination. A short course (prednisone 20–40 mg/day, tapering over 2–4 weeks) is usually sufficient.
- Hydroxychloroquine — useful for sarcoidosis-associated and chronically recurrent EN; has a slower onset but is well tolerated long-term.
- Colchicine — an alternative option occasionally used in recurrent or refractory cases.
Recurrent Erythema Nodosum
Most episodes of EN resolve and do not recur — particularly when the trigger (a streptococcal infection, a medication) is removed. However, some patients experience recurrent bouts. Two prospective series from Istanbul found that relapse pointed away from a hidden disease rather than toward one: nodules came back every year in 62% (33 of 53) and 74% of people with no cause found, but in only one person with an identified cause in each series (Behçet's disease). In the larger series, "recurrence in EN significantly predicted primary EN," meaning EN with no underlying disease. Among 35 children in a Greek study, recurrences were noted in only 2.
Inflammatory bowel disease has been described as the most common driver of recurrent EN, although the two series above did not find that (the only secondary relapses were in Behçet's disease). In ulcerative colitis and Crohn's disease, EN activity characteristically parallels bowel disease activity — flares of bowel inflammation trigger new EN nodules, and effective inflammatory bowel disease treatment reduces both. Clinicians look for hidden inflammatory bowel disease in people with recurrent EN, even in the absence of prominent gastrointestinal symptoms.
Sarcoidosis can also drive recurrent EN, particularly during periods of systemic activity. In Löfgren's syndrome specifically, while the acute episode carries an excellent prognosis, some patients have recurrent EN during subsequent sarcoidosis activity before the disease ultimately remits. Hydroxychloroquine is a useful long-term option in this group.
Potassium iodide has been used for recurrent EN without a clearly treatable underlying cause; the evidence comes from case series such as the 1976 report above and a 1983 report that EN has "been treated successfully" with it, and neither reports a controlled trial. Practitioners describe taking it during active flares or maintaining it at low doses to suppress recurrence.
Idiopathic recurrent EN — when all investigations remain negative despite thorough workup — is described as a reason for periodic re-evaluation. Inflammatory bowel disease can be missed initially, sarcoidosis may manifest only systemically, and an oral contraceptive restarted after a pregnancy can re-trigger the pattern. Practitioners describe colchicine and hydroxychloroquine as the preferred maintenance options in this group.
Key Research Papers
- Requena L, Yus ES. Erythema nodosum. Dermatologic Clinics. 2008;26(4):425–438. — PubMed PMID: 18793974
- Schwartz RA, Nervi SJ. Erythema nodosum: a sign of systemic disease. American Family Physician. 2007;75(5):695–700. — PubMed PMID: 17375516
- Cribier B, Caille A, Heid E, Grosshans E. Erythema nodosum and associated diseases. A study of 129 cases. International Journal of Dermatology. 1998;37(9):667–672. — PubMed PMID: 9762816
- Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R. Erythema nodosum: an experience of 10 years. Scandinavian Journal of Infectious Diseases. 2004;36(6-7):424–427. — PubMed PMID: 15307561
- Blake T, Manahan M, Rodins K. Erythema nodosum — a review of an uncommon panniculitis. Dermatology Online Journal. 2014;20(4):22376. — PubMed PMID: 24746312
- Cohen PR. Sweet's syndrome — a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet Journal of Rare Diseases. 2007;2:34. — PubMed PMID: 17655751
- Mert A, Kumbasar H, Ozaras R, et al. Erythema nodosum: an evaluation of 100 cases. Clinical and Experimental Rheumatology. 2007;25(4):563–570. — PubMed PMID: 17888212
- Kakourou T, Drosatou P, Psychou F, Aroni K, Nicolaidou P. Erythema nodosum in children: a prospective study. Journal of the American Academy of Dermatology. 2001;44(1):17–21. — PubMed PMID: 11148471
- Psychos DN, Voulgari PV, Skopouli FN, Drosos AA, Moutsopoulos HM. Erythema nodosum: the underlying conditions. Clinical Rheumatology. 2000;19(3):212–216. — PubMed PMID: 10870657
- Sasson S, Kalisky I, Rosenfeld G, Kiow JLC, Bressler B. Erythema nodosum as a marker for objective disease activity in inflammatory bowel disease. Crohn's & Colitis 360. 2026;8(1):otag013. — PubMed PMID: 41788361
- Schulz EJ, Whiting DA. Treatment of erythema nodosum and nodular vasculitis with potassium iodide. British Journal of Dermatology. 1976;94(1):75–78. — PubMed PMID: 943168
- Horio T, Danno K, Okamoto H, Miyachi Y, Imamura S. Potassium iodide in erythema nodosum and other erythematous dermatoses. Journal of the American Academy of Dermatology. 1983;9(1):77–81. — PubMed PMID: 6886108